Protocol Title: A Phase I/II randomized, double-blind, placebo-controlled trial (1-BETTER) examining XB2001 (anti-IL-1⍺ True Human antibody) in combination with ONIVYDE + 5-Fluorouracil + Leucovorin in advanced pancreatic cancer

Sponsor: Xbiotech

Protocol Number: 2020-PT049

Key Criteria

·         Documented disease progression after one prior gemcitabine-based therapy OR one FOLFIRINOX and gemcitabine containing therapy.
 
·         Histologically or cytologically confirmed pancreatic adenocarcinoma of exocrine pancreas that is metastatic, unresectable, or recurrent.
 
·         Measurable disease per RECIST 1.1

Talking Points

Scroll to Top